NGNE
Neurogene Inc. · Healthcare
20.47
1.06%(-0.22)
Prev. Close20.96
2.39%(+0.49)
Pre-marketLast Updated: — ET
52W L: $6.8852W H: $37.27
$20.95
CHG-1.20 (-5.42%)
H$24.67
L$18.29
VOL2.2M
NGNE (1h)
Neurogene Inc. · Healthcare
Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year 2025 financial results and highlighted recent corporate updates. “We continue to demonstrate strong execution, with completion of enrollment in the Embolden registrational trial, dosing more than half of participants, and receipt of Breakthrough Therapy designation for NGN-40.
Neurogene (NASDAQ: NGNE) CEO and founder Rachel McMinn outlined the company's progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lead program McMinn described Neurogene as a genetic medicines company developing treatments for "devastating
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's webs.
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,450 shares of the Company's common stock to four new employees (the “Inducement Grants”) on March 2, 2026 (the “Grant Date”). The Inducem.
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts' earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the... Here Are Friday's Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More.
Cvijic Christine Mikail
officer: President and CFO
2,558 SH @ $21.62
2026-03-26
McMinn Rachel
director, officer: Chief Executive Officer
3,352 SH @ $22.07
2026-03-26
Jordan Julie
officer: Chief Medical Officer
828 SH @ $21.89
2026-03-26
Cobb Stuart
officer: Chief Scientific Officer
3,991 SH @ $20.41
2026-03-13
Cobb Stuart
officer: Chief Scientific Officer
2,658 SH @ $21.34
2026-03-13
Cobb Stuart
officer: Chief Scientific Officer
148 SH @ $22.08
2026-03-13
Cvijic Christine Mikail
officer: President and CFO
2,387 SH @ $20.42
2026-03-13
Cvijic Christine Mikail
officer: President and CFO
1,395 SH @ $21.25
2026-03-13